| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity J Barretina, G Caponigro, N Stransky, K Venkatesan, AA Margolin, S Kim, ... Nature 483 (7391), 603-607, 2012 | 7745 | 2012 |
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity J Barretina, G Caponigro, N Stransky, K Venkatesan, AA Margolin, S Kim, ... Nature 483 (7391), 603-607, 2012 | 7697 | 2012 |
| High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response H Gao, JM Korn, S Ferretti, JE Monahan, Y Wang, M Singh, C Zhang, ... Nature medicine 21 (11), 1318-1325, 2015 | 1312 | 2015 |
| An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) M Korpal, JM Korn, X Gao, DP Rakiec, DA Ruddy, S Doshi, J Yuan, ... Cancer discovery 3 (9), 1030-1043, 2013 | 600 | 2013 |
| Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma S Buonamici, J Williams, M Morrissey, A Wang, R Guo, A Vattay, K Hsiao, ... Science translational medicine 2 (51), 51ra70-51ra70, 2010 | 523 | 2010 |
| Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma R Rahal, M Frick, R Romero, JM Korn, R Kridel, F Chun Chan, B Meissner, ... Nature medicine 20 (1), 87-92, 2014 | 396 | 2014 |
| FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor V Guagnano, A Kauffmann, S Wöhrle, C Stamm, M Ito, L Barys, A Pornon, ... Cancer discovery 2 (12), 1118-1133, 2012 | 354 | 2012 |
| Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms P Liu, H Cheng, S Santiago, M Raeder, F Zhang, A Isabella, J Yang, ... Nature medicine 17 (9), 1116-1120, 2011 | 292 | 2011 |
| Rapid changes in the concentration of phosphoenolpyruvate carboxykinase mRNA in rat liver and kidney. Effects of insulin and cyclic AMP. MA Cimbala, WH Lamers, K Nelson, JE Monahan, H Yoo-Warren, ... Journal of Biological Chemistry 257 (13), 7629-7636, 1982 | 241 | 1982 |
| Isolation and characterization of the gene coding for cytosolic phosphoenolpyruvate carboxykinase (GTP) from the rat. H Yoo-Warren, JE Monahan, J Short, H Short, A Bruzel, A Wynshaw-Boris, ... Proceedings of the National Academy of Sciences 80 (12), 3656-3660, 1983 | 230 | 1983 |
| Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer J Lillie, M Gannavarapu, K Glatt, S Hoersch, S Kamatkar, HM Mertens, ... US Patent 7,705,120, 2010 | 135 | 2010 |
| Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis M Ito, L Barys, T O'Reilly, S Young, B Gorbatcheva, J Monahan, ... Clinical Cancer Research 17 (3), 416-426, 2011 | 132 | 2011 |
| A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients R Tiedt, E Degenkolbe, P Furet, BA Appleton, S Wagner, J Schoepfer, ... Cancer research 71 (15), 5255-5264, 2011 | 126 | 2011 |
| Identification of a DNA clone to phosphoenolpyruvate carboxykinase (GTP) from rat cytosol. Alterations in phosphoenolpyruvate carboxykinase RNA levels detectable by hybridization. H Yoo-Warren, MA Cimbala, K Felz, JE Monahan, JP Leis, RW Hanson Journal of Biological Chemistry 256 (20), 10224-10227, 1981 | 118 | 1981 |
| FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors F Li, H Huynh, X Li, DA Ruddy, Y Wang, R Ong, P Chow, S Qiu, A Tam, ... Cancer discovery 5 (4), 438-451, 2015 | 105 | 2015 |
| The specificity of the FOXL2 c. 402C> G somatic mutation: a survey of solid tumors KA Schrader, B Gorbatcheva, J Senz, A Heravi-Moussavi, N Melnyk, ... PloS one 4 (11), e7988, 2009 | 100 | 2009 |
| Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer R Schlegel, J Monahan, W Endege, M Gannavarapu, B Gorbatcheva, ... US Patent App. 10/205,823, 2003 | 95 | 2003 |
| Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer R Schlegel, J Monahan, W Endege, M Gannavarapu, B Gorbatcheva, ... US Patent App. 10/205,823, 2003 | 95 | 2003 |
| The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells Z Jagani, D Wiederschain, A Loo, D He, R Mosher, P Fordjour, ... Cancer research 70 (13), 5528-5538, 2010 | 94 | 2010 |
| Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer R Schlegel, W Endege, J Monahan US Patent App. 10/357,930, 2004 | 74 | 2004 |
Sebastian HoerschInvestigator, Novartis Institutes for Biomedical ResearchVerifierad e-postadress på novartis.com
